Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cereno Scientific to present CS014’s preclinical data at top European cardiology congress ESC Congress 2022

Cereno Scientific (XSAT: CRNO B) today announced that an abstract on preclinical drug candidate CS014 has been accepted at the ESC Congress 2022 hosted by the European Society of Cardiology in Barcelona, Spain, on August 26-29. The abstract has been selected for an oral moderated poster presentation and is titled “CS014 is a novel HDAC inhibitor regulating platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding.” It will be presented by Dr. Michael Holinstat, lead of Cereno’s preclinical development programs at University of Michigan

Scandinavian ChemoTech's subsidiary Vetiqure participates in ESVONC's congress in Italy

Between May 26–28th 2022, our product specialist Elin Wallin and our CEO Mohan Frick will participate in ESVONC's annual congress in Italy. A poster on treatment with our TSE™ technology has been accepted and will also be presented there.The poster that has been accepted is written by Majbritt Larsen, Veterinarian with specialist competence in dog and cat diseases, responsible for Oncology Evidensia Specialist Animal Hospital Helsingborg and presents the outcome from the treatment of sarcoids in a horse, which we published on 16 Nov 2021. Majbritt will herself attend and present her poster

Atlas Copco Capital Markets Day on November 17, 2022

Nacka, Sweden, May 16, 2022: Atlas Copco will host its Capital Markets Day on November 17, 2022, in Stockholm, Sweden.The purpose of the Capital Markets Day is to give an update on the strategy and development of the Atlas Copco Group and its worldwide operations. Participants from Atlas Copco will be Mats Rahmström, President and CEO, Peter Kinnart, CFO, and Business Area Presidents. The program starts in the morning and will be finished before 5 PM CET. Instructions on how to register and more detailed information will be distributed prior to the event.

Save the Date: ASSA ABLOYs Capital Markets Day on 16 November 2022

ASSA ABLOY will hold its Capital Markets Day on 16 November 2022 in London, UK. At the CMD, Nico Delvaux, CEO, and Erik Pieder, CFO, will give an update of ASSA ABLOY’s strategy and direction. Other members of the executive team will also present during the day. More detailed information and instructions on how to register will be distributed prior to the event. The formal program is expected to finish by approximately 4pm.

Invitation to Scandion Oncology webcast and conference call May 19, 2022

Scandion Oncology (Scandion) will publish its Q1 2022 interim report on Thursday, May 19, 2022 before 09:00 CET. Scandion Oncology’s Executive Management will host a webcast and conference call the same day at 10:00 CET presenting the results and a company update. At the end of the presentation there will be a Q&A session.Access to the event can be obtained as follows: LIVE access on Thursday May 19, 2022 at 10:00 CET https://financialhearings.com/event/43547 

MTG to host a live streamed Capital Markets Update on June 21, 2022

STOCKHOLM, Modern Times Group MTG AB (MTG) would like to invite analysts, investors, members of the media and other stakeholders to its live streamed Capital Markets Update. The digital-only event is expected to begin at 13.00 CET, on June 21, 2022.The Capital Markets Update will be streamed live for all participants. A recording, as well as the materials from the event, will be published after the event on www.mtg.com. Guests are cordially invited to register for, and view, the event on this link: https://tv.streamfabriken.com/mtg-capital-markets-update/register   The event will be

Immunovia strengthens its US team through the appointment of Natalie Carfora as Head of Market Access US

LUND, SWEDEN – Immunovia (Nasdaq Stockholm: IMMNOV) has appointed Natalie Carfora as Head of Market Access of its US subsidiary, Immunovia, Inc. Natalie brings deep expertise to the reimbursement process from prior market access roles at Scipher Medicine and Myriad Genetics. Natalie will take up her position on May 23, 2022.   “The hire of Natalie as Head of Market Access in the US is another key hire in-line with our strategic priority to strengthen our US team for a commercial scale up of IMMray™ PanCan-d in the US. Natalie will be instrumental in the pursuit of reimbursement

Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate

· Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures.  · Primary aim is to obtain pharmacokinetic data from this age group and to demonstrate that CT001 is feasible as premedication in children undergoing a painful procedure. · Topline results are anticipated by the end of Q3 2022Cessatech A/S announces that the pharmacokinetic trial (0206) in children has finalised recruitment of all planned patients. The trial is designed as a non-randomised, open-label study in 25 children aged 1-17 years needing

Curasight to present at Kapital Partners Life Science seminar

Curasight A/S (TICKER: CURAS) announced today that Chief Executive Officer Ulrich Krasilnikoff and Chief Scientific Officer professor Andreas Kjær will give an update on company strategy and progress in developing new treatment options for cancer diseases, at Kapital Partners Life Science seminar, 18 May 2022.The presentation will be webcasted live 11:00 - 11:25 (CET), Wednesday 18 May 2022. For more information – please click here 

GO MO DBS, Lead Generation Specialists, Launches UK Expansion – Opens London Office in Covent Garden

Experienced strategic partnership professionals Simon Gregory and Oliver Paull will take the lead when GO MO DBS, specialising in data-driven “outbound marketing”, establishes a new office in Covent Garden, London. The company will bring its demand & lead generation, content syndication and programmatic services to marketing agencies & publishers in the UK. The London office marks the first step of the GO MO brand expansion into the UK and Europe. “GO MO DBS is an innovative company with a core belief that data is the key to everything our partners and their clients need. Demand and lead

Cinis Fertilizer secures power supply to the first production facility

Cinis Fertilizer has signed an agreement with E.ON Energidistribution for a power connection to the company's first planned production facility for environmentally friendly potassium sulfate. The facility in Köpmanholmen will be powered by fossil-free electricity and the first in the world to produce a circular mineral fertilizer from waste products from pulp mills and electric car battery production.Cinis Fertilizer is planning the construction of its first production facility for fossil-free and circular potassium sulfate in Köpmanholmen, south of Örnsköldsvik. The company has now entered

Invitation to presentation of first quarter results 2022, Monday 23.05 at 10.00 CEST

Akobo Minerals AB (publ) will release its first quarter results 2022 on Monday 23 May at 08.30 CEST.The results will be presented in a webcast with CEO Jørgen Evjen and COO Matt Jackson at 10.00 CEST. The presentation and subsequent Q&A session will be held in English and may be viewed live at Akobo Minerals Q1-22 presentation 23.05 at 10.00 - inQrate      For more information, contact:  Jørgen Evjen, CEO, Akobo Minerals  Mob: (+47) 92 80 40 14   Mail: jorgen@akobominerals.com   LinkedIn: www.linkedin.

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Faron Pharmaceuticals Ltd. (“Faron” or “Company”)   Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies   · Phase 1 dose escalation study will evaluate the safety and tolerability of combination therapy and determine the recommended dose for Phase 2 expansion · Patient recruitment will commence in the coming weeks · Supporting pre-clinical bexmarilimab hematology data was presented at recent European Hematology Association 2022 Congress  Company

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022

Full focus on the phase III study CONCLUDE with cobitolimod“With a new management team in place, I look forward to a continued exciting and important year with full focus on the phase III study CONCLUDE with cobitolimod”, says Johan Giléus, acting CEO of InDex Pharmaceuticals. Period January – March 2022 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –18.9 (–9.3) million · Result after tax amounted to SEK –18.9 (–9.3) million, corresponding to SEK –0.04 per share (–0.02) before and after dilution · Cash flow from operating activities amounted

Africa Energy to Present at Frontier Summit

VANCOUVER, BC, May 16, 2022 /CNW/ – Africa Energy Corp. (TSX Venture: AFE) (Nasdaq First North: AEC) (“Africa Energy” or the “Company”), an oil and gas company with exploration assets offshore South Africa and Namibia, announces that the Company’s Principal Geophysicist, Tobias Tonsing, will be presenting at Frontier’s Africa Energies Summit in London, United Kingdom on Thursday, May 19, 2022, at approximately 14:20 British Summer Time. View PDF version  The title of the presentation is, “Upcoming Exploration Drilling in

Stora Enso divests its packaging operations in Russia

STORA ENSO OYJ INVESTOR NEWS 16 May 2022 at 9:00 EESTStora Enso has divested its three corrugated packaging plants in Russia. The Company’s Lukhovitsy, Arzamas and Balabanovo packaging plants have been divested to local management.Stora Enso’s assessment is that due to the uncertainties in the Russian market, local ownership and operation will provide a more sustainable long-term solution for these businesses and their respective employees.   The transaction will have no material impact on Stora Enso’s annual sales and Operational EBIT. Due to reduced business prospects for these

PT027, a novel fixed-dose combination of albuterol and budesonide, used as an as-needed rescue medicine, significantly reduced the risk of a severe exacerbation

First time an albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations. MANDALA Phase III trial results published in the New England Journal of Medicine and presented at ATS 2022 International Conference.Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with

Altor to acquire Nordic Climate Group - becomes majority owner

Altor Fund V (“Altor”) has signed an agreement with Capillar Equity to acquire a majority stake in Nordic Climate Group (”NCG”). Completion is subject to approval of the competition authorities.The entrepreneurs and management of NCG will continue to own a meaningful share of the company.NCG is a services, installations and solutions company within the cooling and heating industry. NCG is the market leader in the Nordics with its full national coverage in Sweden and Norway with 50 legal operating entities. Pro forma revenues as per 30 April 2022 is estimated to be 2.2 bn SEK and NCG

Modus Therapeutics publishes interim report for the first quarter 2022

STOCKHOLM, SWEDEN - 16 May 2022: Modus Therapeutics Holding AB (”Modus Therapeutics”) hereby publishes an interim report for the first quarter 2022. The report is available as an attached document and on the company's website (www.modustx.com). Below is a summary of the interim report.The first quarter in figures · The loss after tax amounted to TSEK 3 065 (1 428). · The loss per share amounted to SEK 0,19 (0,17). · The cash flow from current operations was negative in the amount of TSEK 7 545 (1 166). Important events during the quarter · Modus presented at Erik Penser

US study shows that EIS and Nevisense significantly improves clinicians’ diagnostic accuracy

STOCKHOLM, SWEDEN, — May 16, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new study published in the US demonstrated that EIS and Nevisense can significantly improve clinical decisions in the dermatology day-to-day practice, especially for less experienced clinicians. The study titled – “Diagnostic Efficacy Of Electrical Impedance Spectroscopy Versus Dermoscopy For Pigmented Skin Lesions: A Pilot Study” and authored by Dr Jonathan Ungar, Associate Director and Assistant Professor,

Changes in Oriola Management Team

Oriola Corporation Stock Exchange Release 16 May 2022 at 9.00 a.m. Changes in Oriola Management Team Hannes Hasselrot, currently Vice President, Consumer and Managing Director of Kronans Apotek, has been appointed Oriola Corporation’s Vice President, Oriola Sweden. Until the planned pharmacy joint venture has been approved by the competition authorities and the merger is completed in Sweden, Hasselrot will continue in his current role. Consequently, Oriola Corporation’s CEO Katarina Gabrielson continues to act as interim leader for Oriola Sweden until the planned merger has been

Perfection in its smallest forms

In the NOMOS Glashütte production center, the parts of the in-house watch movements are manufactured like clockwork—that is to say, with high precision and always in the same way. The majority of work that goes into a NOMOS watch is done by hand, just as it was 175 years ago. But when it comes down to the micrometer, cutting-edge technology prevails.GLASHÜTTE, MAY 2022. In the Glashütte district of Schlottwitz is located the modern industrial hall, clad in local larch wood. Inside, CNC-controlled lathes and milling machines are in operation; gear cutting and wire erosion are taking place.

BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT

Bergen, Norway, 16 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, is pleased to announce that CEO Martin Olin will be presenting at the ABG Sundal Collier Life Science Summit taking place on Wednesday 18 May at 11:30 CEST.   The presentation slides will be made available on the Company's website in the Investors section shortly after the presentation.   -Ends- Contacts Martin Olin CEO, BerGenBio ASA ir@bergenbio.com Rune Skeie, CFO, BerGenBio ASArune.skeie@

There are no items matching the current filter
There are no more items matching the current filter
Back to top